Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H13N5O2 |
| Molecular Weight | 235.2425 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC=NC2=C1N=CN2[C@H]3CC[C@@H](CO)O3
InChI
InChIKey=WVXRAFOPTSTNLL-NKWVEPMBSA-N
InChI=1S/C10H13N5O2/c11-9-8-10(13-4-12-9)15(5-14-8)7-2-1-6(3-16)17-7/h4-7,16H,1-3H2,(H2,11,12,13)/t6-,7+/m0/s1
| Molecular Formula | C10H13N5O2 |
| Molecular Weight | 235.2425 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:31:14 UTC 2023
by
admin
on
Sat Dec 16 03:31:14 UTC 2023
|
| Record UNII |
4Q86AH641A
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
20587
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
||
|
NCI_THESAURUS |
C707
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
||
|
NCI_THESAURUS |
C97452
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
223-853-2
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
4097-22-7
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
C429
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
1191237
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
20039
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
4Q86AH641A
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
91207
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
98700
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
DTXSID2023771
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | |||
|
m4382
Created by
admin on Sat Dec 16 03:31:14 UTC 2023 , Edited by admin on Sat Dec 16 03:31:14 UTC 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
In the chromatogram obtained with solution (2), the following peaks are eluted at the following relative retention with reference to didanosine (retention time about 13-15 min): impurity G about 1.6.
The area of any individual peak corresponding to impurity G is not greater than 0.2 times the area of the principal peak obtained with solution (4) (0.2%).
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
